1. Effect of Prolonged Interferon Therapy on the Outcome of Hepatitis C Virus–Related Cirrhosis: A Randomized Trial 
Laetitia Fartoux, Françoise Degos, Christian Trépo, Odile Goria, Paul Calès, Albert Tran, Catherine Buffet, Thierry Poynard, Dominique Capron, Jean–Jacques Raabe, Dominique Roulot, Sylvie Naveau, Jean–Didier Grange, Renée E. Poupon, Raoul Poupon, Lawrence Serfaty 
Clinical Gastroenterology and Hepatology 
Volume 5, Issue 4, Pages (April 2007)
DOI: /j.cgh
Copyright © 2007 AGA Institute Terms and Conditions

2. Figure 1
Distribution of the number of risk factors of complication at baseline in the study population. Risk factors are defined in the Patients and Methods section.
Clinical Gastroenterology and Hepatology 2007 5, DOI: ( /j.cgh )
Copyright © 2007 AGA Institute Terms and Conditions

3. Figure 2
Cumulative probability of complication-free survival according to treatment arm (bold line, treatment; thin line, no treatment).
Clinical Gastroenterology and Hepatology 2007 5, DOI: ( /j.cgh )
Copyright © 2007 AGA Institute Terms and Conditions

4. Figure 3
Cumulative probabilities of HCC occurrence (A) and of HCC-free decompensation (ascites and/or jaundice, variceal bleeding, encephalopathy) (B) according to treatment arm (bold line, treatment; thin line, no treatment).
Clinical Gastroenterology and Hepatology 2007 5, DOI: ( /j.cgh )
Copyright © 2007 AGA Institute Terms and Conditions

5. Figure 4
Course of ALT level, serum bilirubin level, prothrombin time, and serum albumin level in treated (●) and untreated () patients. Values are expressed as mean ± SEM.
Clinical Gastroenterology and Hepatology 2007 5, DOI: ( /j.cgh )
Copyright © 2007 AGA Institute Terms and Conditions

6. Figure 5
Rate of events according to the number of risk factors at baseline. P = .004.
Clinical Gastroenterology and Hepatology 2007 5, DOI: ( /j.cgh )
Copyright © 2007 AGA Institute Terms and Conditions